Skip to main content Accessibility help


  • Access
  • Cited by 33


      • Send article to Kindle

        To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Alzheimer's disease: The amyloid hypothesis on trial
        Available formats

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Alzheimer's disease: The amyloid hypothesis on trial
        Available formats

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Alzheimer's disease: The amyloid hypothesis on trial
        Available formats
Export citation


The pathogenesis of Alzheimer's disease is complex. The amyloid hypothesis has directed research efforts for many years, but it has recently been questioned after failed drug trials. Here, we review the evidence for and against and suggest that it might be premature to abandon the amyloid hypothesis.


Declaration of interest


The amyloid hypothesis of Alzheimer's disease proposes that deposition of beta-amyloid (Aβ) protein is central to the pathogenesis of the disorder. 1 It has been the foundation of efforts to understand the disease for almost 25 years. However, recently its validity has been called into question after the failure of Aβ-targeting therapies in clinical trials. Some have even suggested that the causal link between Aβ and Alzheimer's disease has been refuted. 2

The pathology of Alzheimer's disease

The classical histological features of Alzheimer's disease are a triad of Aβ plaques, neurofibrillary tangles and neuronal cell loss. 3 The first of these are insoluble extracellular plaques consisting of Aβ, which accumulates in very high levels in the brains of those with Alzheimer's disease. Aβ is derived from a larger molecule, amyloid precursor protein (APP). APP is a trans-membrane protein, with a long extracellular N-terminal and a shorter intracellular C-terminal. The Aβ sequence consists of some of the extracellular portion and part of the trans-membrane domain, and is 39–42 amino acids in length. The protein has a β-pleated sheet structure, and demonstrates Congo red birefringence and resistance to proteolysis. 4 In Alzheimer's disease, Aβ is deposited in abundant extracellular plaques typically composed of straight fibrils, 6–10 nm in diameter. These structures are also found in normal ageing but in less profusion and are sometimes referred to as senile plaques. They are associated with dystrophic neurites and changes in microglia and astrocytes. 3 Non-fibrillar, diffuse Aβ deposits, which are not associated with dystrophic neurites or reactive glial cells, are also found in Alzheimer's disease and these may represent an early stage plaque formation. In Alzheimer's disease these diffuse plaques are found throughout the central nervous system, whereas typical Aβ plaques are not present in regions such as the spinal cord and cerebellum. 4

The second pathological structure found in Alzheimer's disease is the neurofibrillary tangle. These consist of dystrophic neurites containing paired helical filaments, 10 nm in diameter. These paired helical filaments consist of a phosphorylated microtubule-associated protein, tau (MAPT). 3 In the 1980s there was much debate as to which one of these is the primary driver of Alzheimer's disease pathogenesis. The issue seemed to be resolved with the advent of a new generation of molecular genetic studies. 5


Early molecular genetic studies of Alzheimer's disease focused on rare families where the disorder occurs exceptionally early and follows an autosomal dominant mode of inheritance. It was discovered that so-called familial Alzheimer's disease is caused by mutations either in the APP gene itself, or in presenilin 1 and 2 (PS1 and PS2) that are involved in cleaving Aβ from APP. 5 In addition, Alzheimer's disease frequently affects those with trisomy 21, who have a triplication of the APP gene. 5 On these grounds, Hardy & Allsop 4 postulated that APP mismetabolism and Aβ deposition are the primary events in the disease process with tau phosphorylation and neurofibrillary tangle formation occurring downstream. This became known as the amyloid hypothesis. It later transpired that the familial Alzheimer's disease genes increase levels of 42 amino acid Aβ (Aβ42) relative to the shorter 40 amino acid protein, and this form of Aβ aggregates more readily into plaques. 6


The hypothesis has received further support from widely replicated biomarker studies. Brain Aβ deposition in Alzheimer's disease can be demonstrated in vivo using biomarkers such as cerebrospinal fluid (CSF) Aβ42 and Aβ positron emission tomography (PET) imaging. 7 Clinical diagnoses of Alzheimer's disease and Aβ pathology at autopsy correlate with low concentrations of CSF Aβ42. Most patients with a diagnosis of Alzheimer's have increased retention of radioligands for Aβ on PET. Moreover, low CSF Aβ and positive Aβ PET show nearly 100% concordance. 7

Thus, a substantial body of evidence appears to support a causative, pathogenic link between Aβ and Alzheimer's disease. However, there are a few pieces of the Alzheimer's jigsaw that do not quite fit.

Challenges to the amyloid hypothesis

Alzheimer's is not an all-or-none phenomenon even at the neuropathological level. Moreover, autopsy studies find sufficient numbers of Aβ plaques and neurofibrillary tangles to meet criteria for a diagnosis of Alzheimer's disease in around a third of cognitively intact elderly people. 8 This is corroborated by biomarker studies, which suggest that 20–40% of elderly people without cognitive impairment show significant brain Aβ load, either on Aβ PET or CSF Aβ42 concentrations. 8

The topographic distribution of Aβ plaques differs from neurofibrillary tangle deposition and neurodegenerative changes. In early Alzheimer's disease, neural loss is predominantly in the hippocampus and entorhinal cortex, whereas plaques are first found in frontal regions, basal ganglia or elsewhere. 7,9 Clinical symptoms are more closely associated with neurofibrillary tangles than Aβ burden. However, cerebral atrophy, representing neuron and synapse loss, corresponds best to cognitive impairment. 10

How distant Aβ plaques might induce neurofibrillary tangles or damage neurons is unclear. It has been proposed that soluble oligomers of Aβ could be neurotoxic. Although soluble oligomers cannot be seen in vivo or post-mortem, they have been found to interfere with postsynaptic potentiation in tissue culture studies. However, the concentration of Aβ oligomers shown to have this effect is greater than usual physiological levels. 11 Another suggestion is that Aβ plaques could act as a ‘reservoir’ eluting soluble Aβ, but Aβ has a strong tendency to polymerise and fix fragments to plaques, which makes this less likely. 11 Furthermore, many animal models based on APP and PS1 mutations have not shown progression to synaptic loss, neurofibrillary tangle formation and neurodegeneration. 6

Critics of the amyloid hypothesis also point out that familial Alzheimer's disease, where the aetiological link with APP is strong, is rare and might be an atypical form of the disorder. They point to recent genome-wide association studies (GWAS), which have implicated many novel genes as containing risk factors for typical Alzheimer's disease but not APP or its metabolising enzymes. In defence of the amyloid hypothesis, GWAS only assess common genetic variation and failure to find association does not exclude an important role for a protein in disease. Moreover, some of the genes implicated by GWAS may be involved in Aβ processing. For example, CLU encodes clusterin, which binds soluble Aβ in animal models, forming complexes that can cross the blood–brain barrier, and PICALM encodes phosphatidylinositol binding clathrin assembly protein, which has been postulated to increase Alzheimer's disease risk through APP processing via endocytic pathways, resulting in changes in Aβ levels. 12

Clinical trials

The biggest challenge to the amyloid hypothesis has come from the failure of phase III trials of anti-Aβ therapies 2 despite promising results in animal models. 6 Critics point to notable therapeutic failures, such as semagacestat, an inhibitor of gamma (γ)-secretase, an enzyme responsible for the cleavage of APP to produce pathogenic Aβ. 13 Participants in the active treatment arm had poorer cognitive outcomes, and the trial was terminated. The trial of immunisation with aggregated human Aβ, AN1792, was halted when some participants developed autoimmune encephalopathy, and there was no effect on disease progression. 14

This raises a key question. Does the failure of these trials effectively refute the amyloid hypothesis? There are two general reasons why this conclusion might be premature. First, there could have been insufficient target engagement. Second, the drugs may have been administered too late in the disease process.

In an analysis of six programmes testing anti-Aβ therapies, Karran & Hardy 15 identified various deficiencies. This suggested that the failure of phase III trials of anti-Aβ agents might be because of problems with pharmacokinetics, dosing, outcome measures etc., rather than shortcomings of the amyloid hypothesis. 15 An analysis by pharmaceutical industry investigators 16 reached a similar verdict: negative trials did not demonstrate sufficient target engagement to assess whether reducing Aβ load could modify the course of Alzheimer's disease.

Early research assumed that abnormal deposition of Aβ is a proximal cause of neurodegeneration in Alzheimer's disease. An alternative model is that production of Aβ at abnormal levels begins much earlier in life, is integral to the inception of the disease process, but the subsequent pathological cascade becomes autonomous. If this were true, anti-Aβ therapies would only be effective if administered early in the disease process. Support for this view comes from biomarker studies showing a clear sequence of abnormalities as the disease progresses. 10 The earliest markers of brain Aβ deposition are reductions in CSF Aβ42 followed by increased Aβ PET tracer uptake. These changes occur in the ‘preclinical’ phase 17 and, by the time cognitive impairment is clinically detected, Aβ markers have plateaued. Subsequently, neuronal injury and neurodegeneration predominate. These are shown by increased CSF tau and cerebral atrophy on structural magnetic resonance imaging. Decreased fluorodeoxyglucose uptake on PET indicates accompanying synaptic dysfunction. These markers, which become abnormal later in the disease, correlate closely with clinical symptoms 7 (Fig. 1).

Fig. 1 Biomarkers of the Alzheimer's pathological cascade.

Beta-amyloid (Aβ) is indicated by low cerebrospinal fluid (CSF) Aβ42 or positron emission tomography (PET) Aβ imaging. Tau neuronal injury and dysfunction is shown by CSF tau or fluorodeoxyglucose-PET. Cerebral atrophy is measured with structural magnetic resonance imaging. MCI, mild cognitive impairment. Reprinted with permission from Elsevier Limited. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119–28.

The failed therapeutic trials may also support this chronological pattern. For example, the AN1792 immunisation, 14 which did not improve cognition and had minimal effect on neural loss, gliosis and tau accumulation, did reverse Aβ deposition. The number of patients followed up, however, was small. This is consistent with the view that, in its later stages, the pathogenic process is not dependent on Aβ deposition, even if it is triggered by it. This means that the timing of any intervention in the Alzheimer's pathological process is crucial. It also makes Aβ levels an equivocal proxy end-point for clinical trials at least in the later stages of the process. 18

Among the strongest recent evidence that reducing Aβ cleavage may protect against Alzheimer's disease is the discovery of a rare mutation in the APP gene that is associated with decreased Aβ synthesis and which protects against Alzheimer's disease and cognitive decline in elderly people. 19 Further support for the amyloid hypothesis has come from recent work using human neural stem-cell-derived cultures in a three-dimensional system to model the effects of familial Alzheimer's disease mutations. They deposited Aβ and aggregates of phosphorylated tau. Furthermore, inhibition of Aβ generation with β- or γ-secretase inhibitors decreased both Aβ and tau. 19


The emerging evidence suggests that Aβ deposition occurs early in Alzheimer's disease, and the correct timing of interventions may turn out to be crucial. Identifying asymptomatic individuals who have Aβ-related neurodegeneration will be important, as not all patients currently selected for Alzheimer's disease drug trials have Aβ-positive PET imaging. 20 Trials of anti-Aβ therapy in cognitively normal elderly people with positive Aβ biomarkers and younger, asymptomatic, individuals who carry a familial Alzheimer's disease mutation are underway 21,22 and, if successful, will support the need for anti-Aβ therapies to be given before cognitive decline has become established.

There is increasing interest in the possibility that the key to treating the disorder may be to identify those at risk long before they develop symptoms, as hyperlipidaemia and hypertension are treated years before myocardial or cerebral infarction. This will require the right anti-Aβ drugs to be given to the right patients, those at high risk and at the right time, before irreversible changes have taken place. 10 This will require much further research. Although biomarkers can detect asymptomatic amyloidosis, large longitudinal studies will be needed to investigate their usefulness as predictive tests. 11 Genetic profiling may also have a role, using risk profile scores based on panels of single nucleotide polymorphisms that are associated with increased risk. 12

Despite two decades of intensive work, the amyloid hypothesis has not led to the hoped for therapeutic advances. This has caused some to question its validity and to ask whether efforts aimed at reducing Aβ synthesis are ever likely to be successful. The finding of a mutation in APP that protects against Alzheimer's disease and reduces the production of Aβ suggests that it may be premature to write off the amyloid hypothesis. Moreover, the negative results of therapeutic trials should be interpreted in the light of evidence that Aβ deposition occurs early in the preclinical phase of the illness. The emerging paradigm of targeting treatments at asymptomatic high-risk individuals remains untested, but if this gains support, it will signal a sea change in the way in which Alzheimer's disease is treated with a move from tertiary to secondary prevention.


1 Hardy, JA, Higgins, GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184–5.
2 Drachman, DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement 2014; 10: 372–80.
3 Selkoe, DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487–98.
4 Hardy, J, Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12: 383–8.
5 Tanzi, RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006296.
6 Sambamurti, K, Vasudevaraju, P, Mintzer, J, Bachman, D, Granholm, C. Can the failure of Alzheimer's disease clinical trials be stepping stones to ultimate success: is the amyloid hypothesis discredited by animal models. J Alzheimers Dis Parkinsonism 2012; 2: e115.
7 Jack, CR, Knopman, DS, Jagust, WJ, Shaw, LM, Aisen, PS, Weiner, MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119–28.
8 Rodrigue, KM, Kennedy, KM, Devous, MD, Rieck, JR, Hebrank, AC, Diaz-Arrastia, R, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012; 78: 387–95.
9 Braak, H, Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351–7.
10 Jack, CR, Knopman, DS, Jagust, WJ, Petersen, RC, Weiner, MW, Aisen, PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207–16.
11 Karran, E, Mercken, M, De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698712.
12 Harold, D, Abraham, R, Hollingworth, P, Sims, R, Gerrish, A, Hamshere, ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088–93.
13 Doody, RS, Raman, R, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369: 341–50.
14 Gilman, S, Koller, M, Black, RS, Jenkins, L, Griffith, SG, Fox, NC, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553–62.
15 Karran, E, Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014; 76: 185205.
16 Toyn, JH, Ahlijanian, MK. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther 2014; 6: 14.
17 Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280–92.
18 Hyman, BT, Sorger, P. Failure analysis of clinical trials to test the amyloid hypothesis. Ann Neurol 2014; 76: 159–61.
19 Choi, SH, Kim, YH, Hebisch, M, Sliwinski, C, Lee, S, D'Avanzo, C, et al. A three-dimensional human neural cell culture model of Alzheimer/'s disease. Nature 2014; 515: 274–8.
20 Vellas, B, Carrillo, MC, Sampaio, C, Brashear, HR, Siemers, E, Hampel, H, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013; 9: 438–44.
21 Sperling, RA, Rentz, DM, Johnson, KA, Karlawish, J, Donohue, M, Salmon, DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13.
22 Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 2012; 11: 657–60.